Clinical Trials Logo
  1. Home
  2. Idiopathic Gastroparesis
  3. NCT00765895

Nortriptyline for Idiopathic Gastroparesis — NORIG  

Idiopathic Gastroparesis Clinical Trial

Official title:
Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)

Clinical Trial Summary

The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether treatment with nortriptyline will improve gastroparesis symptoms compared with placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00765895
Study type Interventional
Source National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact
Status Completed
Phase Phase 3
Start date January 2009
Completion date October 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02232334 - Effects of Global Osteopathic Manual Treatments in Patients With Idiopathic Gastroparesis N/A
Completed NCT03544229 - A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis Phase 2
Completed NCT02732821 - G-POEM for Treatment of Refractory Gastroparesis
Completed NCT01916460 - Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients N/A
Completed NCT01696747 - Gastroparesis Registry 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Active, not recruiting NCT03680859 - Gastroparesis Registry 3
Terminated NCT01625923 - A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis N/A
Completed NCT03281577 - Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants Phase 2
Enrolling by invitation NCT03176927 - Biomagnetic Characterization of Gastric Dysrhythmias III N/A
Recruiting NCT04028492 - Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis Phase 3
Completed NCT04303195 - A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis Phase 2